Cannabis Law Report

AUGUST 14, 2021

The deal signed in March had sought to progress an over-the-counter medicine with the TGA using Emyria’s EMD-003 program and Cann’s Gelpell technology. Cann Group (CAN) and Emyria (EMD) mutually agree to drop a deal for the proposed registration of a Schedule 3 cannabidiol (CBD) product.

CBD 105

CBD Clinical Trials Programs Food 105

Cannabis Law Report

FEBRUARY 24, 2022

Canada’s Special Access Program (SAP) allows health care professionals to request drugs for patients with serious or life-threatening conditions where other available treatments fail to work (analogous to the Right to Try (RTT) program in the United States ). Timeline of Medicinal Legalization in Canada. Pursuant to subsection C.08.010(1)

Therapy 52

Therapy Access Clinical Trials Treatment 52

Cannabis Law Report

DECEMBER 9, 2021

The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program. Simister have extensive backgrounds in stroke management as well as clinical care and stroke research.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JUNE 17, 2021

Jazz said it expects to generate 65% of 2022 revenues from products that have been launched or acquired since 2019. As part of our continued R&D efforts we also look forward to advancing our PTSD and essential tremor programs, the nabiximols clinical trial program to support a U.S. 13.40 – $14.70.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

The Cannigma

FEBRUARY 1, 2023

Unlike healthy cells, these abnormal cells don’t die as they are typically programmed to do, and instead begin to grow and divide uncontrollably, effectively circumventing the body’s normal checks and balances. To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

FEBRUARY 9, 2022

If approved by shareholders, the demerger gives Reset the opportunity to solely focus on developing is psychedelics business, and will become its own unlisted entity during the June 2022 quarter. “We

Clinical Trials 52

Clinical Trials Research and Development Medicine Business 52

Cannabis Law Report

APRIL 13, 2022

Apr 12, 2022, 07:00 ET. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Transaction expected to close in June 2022 , following anticipated shareholder approval. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

AUGUST 17, 2021

Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. Conference Call and Webcast Details. Marinus will host a conference call and webcast with slides at 4:30 p.m.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

DECEMBER 26, 2021

In furtherance of its program, the Company filed US Provisional Patent Application No. “Entheon is proud to be making significant strides in its Entheon IQ™ program,” says Timothy Ko, Chief Executive Officer of Entheon. EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. April 5, 2022.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

JANUARY 12, 2022

11, 2022 (GLOBE NEWSWIRE) — Gb Sciences, Inc. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” LAS VEGAS, Jan. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. 31, 2021.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

MAY 10, 2022

11 May 2022. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions. Here’s the Uni of Sydney press release.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

SEPTEMBER 12, 2022

08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. VANCOUVER, British Columbia, Sept. Penis Envy. Blue Pulaski.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

MAY 29, 2022

Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JANUARY 19, 2022

January 17, 2022. – January 17, 2022) – Psygen Industries Ltd. received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “). received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Cannabis Law Report

FEBRUARY 3, 2022

Together with its wide network of research partners, MediCane is executing clinical programs to develop cannabis-based drugs with two leading therapeutic areas – Behavioral and Psychological Symptoms of Dementia (BPSD) and sleep disorders.

Clinical Trials 52

Clinical Trials Research and Development Packaging Oil 52

Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. This level of understanding can inform best practices, improve outcomes, and contribute to sensible policy-making both in Oregon and beyond. ABOUT MAYA.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

SEPTEMBER 23, 2022

SB 57 – which passed both houses – would have created a pilot program for overdose prevention sites in San Francisco, Oakland, and Los Angeles as an evidence-based intervention to curb drug overdose deaths. September 1, 2022. ABOUT MAPS.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Cannabis Law Report

SEPTEMBER 2, 2021

– Company’s safeCircle™ Testing Program to Monitor for COVID-19 Among On-Campus Unvaccinated Populations –. Under the Contract, ADCL will deploy safeCircle™, its high-throughput, pooled COVID-19 testing program, to provide cost-effective COVID-19 testing. STONY BROOK, N.Y.–(BUSINESS

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Canna Law Blog

JANUARY 3, 2023

With the passage of the 2014 Farm Bill , CBD derived from hemp — if cultivated pursuant to a state research pilot program — got a little bit of precarious legal cover. A multitude of states now allow CBD in food and drinks for consumption by humans and animals. The future of FDA CBD regulations.

CBD 75

CBD Food Clinical Trials Pets 75

Cannabis Law Report

JUNE 19, 2022

Although more mental health services are provided by social workers than all other disciplines combined, no other social work program in the country is engaged in this type of work that Dr. Davis and his colleagues are undertaking,” said College of Social Work Dean Tom Gregoire. Jason Slot.

Education 52

Education Research and Development Therapy Clinical Trials 52

Cannabis Law Report

NOVEMBER 26, 2021

Corporate and Clinical Development Highlights Include: Completed Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. Topline results are expected in Q1 2022. Fortified Balance Sheet. On September 30, 2021, Can-Fite had approximately $13.3 Financial Results.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Cannabis Law Report

DECEMBER 2, 2021

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Applicants must also authorize their training program to conduct a criminal background check. Conducting a Psilocybin Administration Session (20 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

DECEMBER 6, 2021

“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinical trial of our lead precision kidney medicine candidate, in mid-2022.”. in Chemistry from Gonzaga University.

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

MARCH 3, 2022

If everything works out in the production and research phase, there is a clause in the license that will allow it to be expanded to clinical trials. The eventual trials would target PTSD, addiction, alcoholism, depression, and anxiety. This would add to the wave of research beginning in the U.S. and Europe.

Research and Development 52

Research and Development Medicine Clinical Trials Microdosing 52

Cannabis Law Report

NOVEMBER 29, 2021

The potential real-life impact – keeping in mind that these data were generated under stringent clinical trial conditions and without any tailoring to the specific needs of the individual – could be even more transformative for those patients suffering from TRD. TRD is just the beginning.

Treatment 52

Treatment Clinical Trials Data Patients 52

Cannabis Law Report

MAY 1, 2022

The potential for OHA to deny or delay approval to entheogenic practitioners who apply for training program approval because they lack access to a licensed service center to satisfy the required practicum. April 20, 2022. Join Chacruna’s Studies in Psychedelic Justice Studies. OHA’s Authority to Regulate for Religious/Spiritual Use.

Safety 52

Safety History Programs Clinical Trials 52

Cannabis Law Report

NOVEMBER 15, 2021

The Company is developing this product candidate as a prophylactic treatment against SARS and influenza and has engaged Syneos Health to assist with the optimal clinical trial design. Sinclair is expected to begin the preclinical animal studies at the beginning of 2022 as part of the enabling trials for an IND application with the FDA.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

JULY 21, 2022

JULY 21, 2022. Cannabis legalization is here, and Congress needs to get with the program.” You might not be so excited to learn there are 296 pages of draft legislation to be read which implies to us that the amendment conversation could still be happening when Kyle Jenner is voted president in 2040.

Safety 52

Safety Legislation Clinical Trials Banking 52

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. In the US, hopes of a quick federal cannabis legalisation in 2022 are fading, but a long shot such as cannabis having a major impact on COVID transmission or remission could speed things up.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

DECEMBER 21, 2021

Prakat swiftly modernizes legacy business hardware, software programs, and downloadable apps. The school’s new location will be opening up in Q1 of 2022 to further ease the shortage and tension of much-needed healthcare workers. Digital Accessibility Compliance – More than 1 billion people live with a disability.

Research and Development 52

Research and Development Supply Chain Data Business 52